Covered recipient · General Payments record
CLAUDIA M ANGULO
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$2,601.42
- Reported across 115 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $341.93 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| BOSTON SCIENTIFIC CORPORATION | $57.49 | 2 |
| Amgen Inc. | $50.07 | 3 |
| CVRx Inc. | $47.82 | 2 |
| Medtronic, Inc. | $43.85 | 2 |
| PFIZER INC. | $39.67 | 2 |
| Novo Nordisk AS | $23.01 | 1 |
| Inspire Medical Systems, Inc. | $21.82 | 1 |
| CARDIVA MEDICAL, INC. | $19.92 | 1 |
| Kiniksa Pharmaceuticals International, plc | $19.25 | 1 |
| Merck Sharp & Dohme Corporation | $19.03 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $16.21 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115425952 | CMS |
| Amgen Inc. | $19.53 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115425956 | CMS |
| Amgen Inc. | $14.33 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115425959 | CMS |
| Boston Scientific Corporation | $29.72 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092677451 | CMS |
| Boston Scientific Corporation | $27.77 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092677449 | CMS |
| CARDIVA MEDICAL, INC. | $19.92 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143863343 | CMS |
| CVRx, Inc. | $23.45 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126034296 | CMS |
| CVRx, Inc. | $24.37 | 11/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126034298 | CMS |
| Inspire Medical Systems, Inc. | $21.82 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148131914 | CMS |
| Kiniksa Pharmaceuticals International, plc | $19.25 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154877792 | CMS |
| Medtronic, Inc. | $26.51 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117000264 | CMS |
| Medtronic, Inc. | $17.34 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117000266 | CMS |
| Merck Sharp & Dohme LLC | $19.03 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141909034 | CMS |
| Novo Nordisk Inc | $23.01 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100295473 | CMS |
| PFIZER INC. | $16.53 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131750890 | CMS |
| PFIZER INC. | $23.14 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131124346 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.